IL-17A, calgranulin C (S100A12), and the activation marker human leukocyte antigen (HLA)-DR were significantly elevated in HS lesional skin and showed a decrease in expression levels when treated with apremilast in an ex vivo HS model [28]. The gene discussed is IL17A; the disease is histiocytic sarcoma.